This study synthesized the current evidence on combined therapy with CD19 and CD20 or CD22 CAR T-cells and compared the efficacy and safety of combining CD19 with CD20 or CD22 CAR T-cells for the treatment of hematological malignancies. The gene discussed is CD19; the disease is hematologic disorder.